

Result: Had an IC₅₀ value of 0.009 μM for PRMT5 in SDMA cells.

In Vivo

TNG908 (1-120 mg/kg twice daily for 21 days, p.o. or i.v.) A promotes tumor regression in LU99 NSCLC cell line-derived xenograft mouse model^[1].

Pharmacokinetic Analysis in SD Rats^[1]

Route	Dose (mg/kg)	clearance (mL/min/kg)	V _{ss_obs} (L/kg)	T _{1/2} (h)	C _{max} (μg/mL)	AUC _{INF} (μg·h/mL)
p.o.	1	38.2	1.5	2	/	/
p.o.	3	/	/	/	0.6	2.5

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. K. Briggs, et al. TNG908 is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for the treatment of MTAP-deleted cancer. MOLECULAR TARGETED AGENTS 2 | VOLUME 174, SUPPLEMENT 1, S84, OCTOBER 2022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA